16-3729218-C-T

Variant summary

Our verdict is Benign. The variant received -14 ACMG points: 0P and 14B. BP4_StrongBP6BP7BS1BS2

The NM_004380.3(CREBBP):​c.5829G>A​(p.Pro1943Pro) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00185 in 1,525,842 control chromosomes in the GnomAD database, including 6 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.0011 ( 0 hom., cov: 31)
Exomes 𝑓: 0.0019 ( 6 hom. )

Consequence

CREBBP
NM_004380.3 synonymous

Scores

2

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:1B:6

Conservation

PhyloP100: -5.26

Publications

1 publications found
Variant links:
Genes affected
CREBBP (HGNC:2348): (CREB binding protein) This gene is ubiquitously expressed and is involved in the transcriptional coactivation of many different transcription factors. First isolated as a nuclear protein that binds to cAMP-response element binding protein (CREB), this gene is now known to play critical roles in embryonic development, growth control, and homeostasis by coupling chromatin remodeling to transcription factor recognition. The protein encoded by this gene has intrinsic histone acetyltransferase activity and also acts as a scaffold to stabilize additional protein interactions with the transcription complex. This protein acetylates both histone and non-histone proteins. This protein shares regions of very high sequence similarity with protein p300 in its bromodomain, cysteine-histidine-rich regions, and histone acetyltransferase domain. Mutations in this gene cause Rubinstein-Taybi syndrome (RTS). Chromosomal translocations involving this gene have been associated with acute myeloid leukemia. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Feb 2009]
CREBBP Gene-Disease associations (from GenCC):
  • Rubinstein-Taybi syndrome
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen, Illumina
  • Rubinstein-Taybi syndrome due to CREBBP mutations
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, G2P
  • Menke-Hennekam syndrome 1
    Inheritance: AD Classification: STRONG Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -14 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.78).
BP6
Variant 16-3729218-C-T is Benign according to our data. Variant chr16-3729218-C-T is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 158389.
BP7
Synonymous conserved (PhyloP=-5.26 with no splicing effect.
BS1
Variant frequency is greater than expected in population sas. GnomAd4 allele frequency = 0.00112 (168/150216) while in subpopulation SAS AF = 0.00445 (21/4716). AF 95% confidence interval is 0.00298. There are 0 homozygotes in GnomAd4. There are 82 alleles in the male GnomAd4 subpopulation. Median coverage is 31. This position passed quality control check.
BS2
High AC in GnomAd4 at 168 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CREBBPNM_004380.3 linkc.5829G>A p.Pro1943Pro synonymous_variant Exon 31 of 31 ENST00000262367.10 NP_004371.2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CREBBPENST00000262367.10 linkc.5829G>A p.Pro1943Pro synonymous_variant Exon 31 of 31 1 NM_004380.3 ENSP00000262367.5 Q92793-1
CREBBPENST00000382070.7 linkc.5715G>A p.Pro1905Pro synonymous_variant Exon 30 of 30 1 ENSP00000371502.3 Q92793-2

Frequencies

GnomAD3 genomes
AF:
0.00112
AC:
168
AN:
150106
Hom.:
0
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.000172
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000133
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00445
Gnomad FIN
AF:
0.00424
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00138
Gnomad OTH
AF:
0.000488
GnomAD2 exomes
AF:
0.00143
AC:
187
AN:
130350
AF XY:
0.00183
show subpopulations
Gnomad AFR exome
AF:
0.000312
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.000127
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00401
Gnomad NFE exome
AF:
0.00178
Gnomad OTH exome
AF:
0.000499
GnomAD4 exome
AF:
0.00193
AC:
2653
AN:
1375626
Hom.:
6
Cov.:
35
AF XY:
0.00201
AC XY:
1366
AN XY:
678032
show subpopulations
African (AFR)
AF:
0.000255
AC:
8
AN:
31396
American (AMR)
AF:
0.0000282
AC:
1
AN:
35466
Ashkenazi Jewish (ASJ)
AF:
0.0000804
AC:
2
AN:
24878
East Asian (EAS)
AF:
0.00
AC:
0
AN:
35636
South Asian (SAS)
AF:
0.00341
AC:
268
AN:
78544
European-Finnish (FIN)
AF:
0.00440
AC:
149
AN:
33828
Middle Eastern (MID)
AF:
0.000988
AC:
4
AN:
4050
European-Non Finnish (NFE)
AF:
0.00201
AC:
2159
AN:
1074412
Other (OTH)
AF:
0.00108
AC:
62
AN:
57416
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.476
Heterozygous variant carriers
0
128
256
384
512
640
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
88
176
264
352
440
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00112
AC:
168
AN:
150216
Hom.:
0
Cov.:
31
AF XY:
0.00112
AC XY:
82
AN XY:
73312
show subpopulations
African (AFR)
AF:
0.000172
AC:
7
AN:
40812
American (AMR)
AF:
0.000132
AC:
2
AN:
15110
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3440
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5088
South Asian (SAS)
AF:
0.00445
AC:
21
AN:
4716
European-Finnish (FIN)
AF:
0.00424
AC:
44
AN:
10370
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
292
European-Non Finnish (NFE)
AF:
0.00138
AC:
93
AN:
67420
Other (OTH)
AF:
0.000483
AC:
1
AN:
2070
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.481
Heterozygous variant carriers
0
7
15
22
30
37
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
4
8
12
16
20
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00105
Hom.:
0
Bravo
AF:
0.000737

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:1Benign:6
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Uncertain:1Benign:2
Nov 29, 2019
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jan 30, 2015
Eurofins Ntd Llc (ga)
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

May 01, 2025
CeGaT Center for Human Genetics Tuebingen
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

CREBBP: BP4, BP7 -

not specified Benign:1
Feb 08, 2013
Genetic Services Laboratory, University of Chicago
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

CREBBP-related disorder Benign:1
Jul 13, 2021
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Rubinstein-Taybi syndrome Benign:1
Jan 30, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Inborn genetic diseases Benign:1
May 03, 2016
Ambry Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.78
CADD
Benign
5.8
DANN
Benign
0.70
PhyloP100
-5.3
Mutation Taster
=98/2
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs546554430; hg19: chr16-3779219; COSMIC: COSV106054294; API